Bioequivalency Study of Meloxicam Tablets Under Fed Conditions
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' Meloxicam
tablets, 15 mg, to Mobic® Tablets, 15 mg (Boehringer Ingelheim) under fed conditions using a
single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.